{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:46Z","timestamp":1793225986717,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010842","name":"Guangzhou Municipal Health and Family Planning Commission","doi-asserted-by":"publisher","award":["2023C-DZ06"],"award-info":[{"award-number":["2023C-DZ06"]}],"id":[{"id":"10.13039\/501100010842","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03258-5","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T03:56:16Z","timestamp":1732161376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiaxi","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"6","key":"3258_CR1","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jtho.2019.02.031","volume":"14","author":"J Remon","year":"2019","unstructured":"Remon J, Reguart N, Auclin E, Besse B. Immune-related adverse events and outcomes in patients with Advanced Non-small Cell Lung Cancer: a predictive marker of efficacy? J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2019;14(6):963\u20137.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"22","key":"3258_CR2","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-small-cell Lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"key":"3258_CR3","unstructured":"Wang HA-O, Guo XA-O, Zhou J, Li Y, Duan L, Si XA-O, Zhang L, Liu X, Wang M, Shi J et al. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. (1759\u20137714 (Electronic))."},{"issue":"12","key":"3258_CR4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with Advanced Cancer: a systematic review and Meta-analysis. JAMA Oncol. 2016;2(12):1607\u201316.","journal-title":"JAMA Oncol"},{"issue":"3","key":"3258_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, Version 1.2020. J Natl Compr Cancer Network: JNCCN. 2020;18(3):230\u201341.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"1","key":"3258_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"23","key":"3258_CR7","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1111\/1759-7714.14693","volume":"13","author":"W Wang","year":"2022","unstructured":"Wang W, Wang Q, Xu C, Li Z, Song Z, Zhang Y, Cai X, Zhang S, Lian B, Li W, et al. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. Thorac cancer. 2022;13(23):3420\u201330.","journal-title":"Thorac cancer"},{"key":"3258_CR8","doi-asserted-by":"crossref","unstructured":"Balaji A, Hsu M, Lin CT, Feliciano J, Marrone K, Brahmer JR, Forde PM, Hann C, Zheng L, Lee V et al. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer 2021, 9(1).","DOI":"10.1136\/jitc-2020-001731"},{"key":"3258_CR9","unstructured":"Pan L, Meng F, Wang W, Wang XH, Shen H, Bao P, Kang J, Kong D. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: a case report and literature review. (1664\u20133224 (Electronic))."},{"key":"3258_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jconrel.2016.01.056","volume":"225","author":"M Guada","year":"2016","unstructured":"Guada M, Beloqui A, Kumar MN, Pr\u00e9at V, Dios-Vi\u00e9itez Mdel C, Blanco-Prieto MJ. Reformulating cyclosporine A (CsA): more than just a life cycle management strategy. J Controlled Release: Official J Controlled Release Soc. 2016;225:269\u201382.","journal-title":"J Controlled Release: Official J Controlled Release Soc"},{"issue":"10309","key":"3258_CR11","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S0140-6736(21)01826-2","volume":"398","author":"KA Johannson","year":"2021","unstructured":"Johannson KA, Chaudhuri N, Adegunsoye A, Wolters PJ. Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet (London England). 2021;398(10309):1450\u201360.","journal-title":"Lancet (London England)"},{"key":"3258_CR12","unstructured":"Lai KC, Hsiao YH, Chen SC. Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: case report and review. (1664\u20133224 (Electronic))."},{"issue":"2","key":"3258_CR13","first-page":"201","volume":"4","author":"JW Raschko","year":"1989","unstructured":"Raschko JW, Cottler-Fox M, Abbondanzo SL, Torrisi JR, Spitzer TR, Deeg HJ. Pulmonary fibrosis after bone marrow transplantation responsive to treatment with prednisone and cyclosporine. Bone Marrow Transpl. 1989;4(2):201\u20135.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"3258_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1080\/08923973.2020.1729176","volume":"42","author":"K Liu","year":"2020","unstructured":"Liu K, Zhan Z, Gao W, Feng J, Xie X. Cyclosporine attenuates paraquat-induced mitophagy and pulmonary fibrosis. Immunopharmacol Immunotoxicol. 2020;42(2):138\u201346.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"3258_CR15","doi-asserted-by":"crossref","unstructured":"Ibrahim SA-O, Abdallah HA-O, El-Halawany AA-O, Mohamed GA-O, Alhaddad AA, Samman WA, Alqarni AA, Rizq AT, Ghazawi KF, El-Dine RS. Natural Reno-Protective Agents against Cyclosporine A-Induced Nephrotoxicity: An Overview. LID \u2013\u200910.3390\/molecules27227771 [doi] LID \u2013\u20097771. (1420\u20133049 (Electronic)).","DOI":"10.3390\/molecules27227771"},{"key":"3258_CR16","doi-asserted-by":"publisher","first-page":"175883591989575","DOI":"10.1177\/1758835919895753","volume":"12","author":"B Zhao","year":"2020","unstructured":"Zhao B, Zhao H, Zhao J. Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer. Ther Adv Med Oncol. 2020;12:1758835919895753.","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 62","key":"3258_CR17","first-page":"PA2959","volume":"52","author":"B Paloma Millan","year":"2018","unstructured":"Paloma Millan B, Iv\u00e1n C, Laura Martinez M, Francisco A, Tom\u00e1s F, Oriol Sibila V, Diego Castillo V. Diagnostic value of serum KL-6 in interstitial lung disease: preliminary results from an European cohort. Eur Respir J. 2018;52(suppl 62):PA2959.","journal-title":"Eur Respir J"},{"key":"3258_CR18","unstructured":"Ishikawa N, Hattori N, Fau - Yokoyama A, Yokoyama A, Fau - Kohno N, Kohno N. Utility of KL-6\/MUC1 in the clinical management of interstitial lung diseases. (2212\u20135353 (Electronic))."},{"issue":"1","key":"3258_CR19","doi-asserted-by":"publisher","first-page":"1722023","DOI":"10.1080\/2162402X.2020.1722023","volume":"9","author":"KH Kim","year":"2020","unstructured":"Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology. 2020;9(1):1722023.","journal-title":"Oncoimmunology"},{"issue":"10","key":"3258_CR20","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1172\/JCI128654","volume":"129","author":"K Suresh","year":"2019","unstructured":"Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM, et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Invest. 2019;129(10):4305\u201315.","journal-title":"J Clin Invest"},{"issue":"17","key":"3258_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJMc1910393","volume":"381","author":"C Ponticelli","year":"2019","unstructured":"Ponticelli C, Moroni G. Rituximab or Cyclosporine for Membranous Nephropathy. N Engl J Med. 2019;381(17):1688\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"3258_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s10020-023-00758-8","volume":"29","author":"C Xu","year":"2023","unstructured":"Xu C, Ye Z, Jiang W, Wang S, Zhang H. Cyclosporine a alleviates colitis by inhibiting the formation of neutrophil extracellular traps via the regulating pentose phosphate pathway. Mol Med (Cambridge Mass). 2023;29(1):169.","journal-title":"Mol Med (Cambridge Mass)"},{"issue":"1","key":"3258_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","volume":"38","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifir\u00f2 G, De Luca A. Myasthenia Gravis Treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs. 2024;38(1):15\u201332.","journal-title":"CNS Drugs"},{"key":"3258_CR24","doi-asserted-by":"publisher","first-page":"204062072210977","DOI":"10.1177\/20406207221097780","volume":"13","author":"B Fattizzo","year":"2022","unstructured":"Fattizzo B, Cantoni S, Giannotta JA, Bandiera L, Zavaglia R, Bortolotti M, Barcellini W. Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers. Therapeutic Adv Hematol. 2022;13:20406207221097780.","journal-title":"Therapeutic Adv Hematol"},{"issue":"5","key":"3258_CR25","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1084\/jem.168.5.1649","volume":"168","author":"A Granelli-Piperno","year":"1988","unstructured":"Granelli-Piperno A. In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J Exp Med. 1988;168(5):1649\u201358.","journal-title":"J Exp Med"},{"key":"3258_CR26","unstructured":"Duan R, Xie L, Li H, Wang R, Liu X, Tao T, Yang S, Gao Y, Lin X, Su W. Insights gained from single-cell analysis of immune cells on Cyclosporine A treatment in autoimmune uveitis. (1873\u20132968 (Electronic))."},{"key":"3258_CR27","unstructured":"Laupacis A, Fau - Keown PA. Keown Pa Fau - Ulan RA, Ulan Ra Fau - McKenzie N, McKenzie N Fau - Stiller CR, Stiller CR: Cyclosporin A: a powerful immunosuppressant. (0008-4409 (Print))."},{"key":"3258_CR28","unstructured":"Rodrigues-Diez R, Gonz\u00e1lez-Guerrero C, Oca\u00f1a-Salceda C, Rodrigues-Diez RR, Egido J, Ortiz A, Ruiz-Ortega M, Ramos AM. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. (2045\u20132322 (Electronic))."},{"issue":"suppl4","key":"3258_CR29","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K. Management of toxicities from immunotherapy: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Annals Oncology: Official J Eur Soc Med Oncol. 2017;28(suppl4):iv119\u201342.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03258-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03258-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03258-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T04:02:51Z","timestamp":1732161771000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03258-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3258"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03258-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3374525\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable: Ethical approval for this case report was not requested. All data in this case were derived from the patient\u2019s routine course of treatment with traceability and no experimental interventions or other manipulations beyond standard medical practice were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"577"}}